8 Compared with placebo, once weekly tirzepatide significantly reduced the combined risk of cardiovascular death or worsening HF events (hospitalisation or an urgent hospital visit requiring intravenous therapy)
In this review, youll gain deep insight into Nooms unique microdose and full-dose GLP-1 protocols, real user experiences, clinical effectiveness, cost structure, and how Noom stacks up against competitors
During treatment: In clinical trials, people reached target doses ranging from 0.5mg to 12mg weekly, depending on their assigned group
Tirzepatide (Mounjaro) , a dual GIP/GLP-1 receptor agonist, has been under NICE appraisal for weight management
10: Goetz IA, Kanu C, Hoover A, Jimenez-Moreno C, Karn H, Kimel M, Neff LM, Boye KS